| Unknown | ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) NCT04669587 | EnhancedBio USA Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy NCT04692103 | University of Washington | Phase 2 |
| Completed | T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer NCT03554044 | University of California, San Francisco | Phase 1 |
| Withdrawn | Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Can NCT03091842 | University of Southern California | N/A |
| Completed | 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer NCT03831711 | Andrei Iagaru | Phase 1 / Phase 2 |
| Completed | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis NCT03691493 | Emory University | Phase 2 |
| Completed | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors NCT03725436 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative NCT03723928 | SWOG Cancer Research Network | N/A |
| Withdrawn | Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Can NCT03666819 | Mayo Clinic | Phase 2 |
| Withdrawn | Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HE NCT03377101 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen R NCT03566485 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Completed | Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors NCT03523195 | Fred Hutchinson Cancer Center | N/A |
| Active Not Recruiting | Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Can NCT03359954 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Me NCT03070002 | Northwestern University | Phase 2 |
| Recruiting | Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Can NCT03213041 | Northwestern University | Phase 2 |
| Withdrawn | Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer NCT03042897 | University of Southern California | N/A |
| Terminated | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage NCT03128619 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative NCT03132467 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carci NCT02993159 | Northwestern University | Phase 2 |
| Completed | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Perit NCT02657928 | Mayo Clinic | Phase 2 |
| Completed | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative NCT02648477 | City of Hope Medical Center | Phase 2 |
| Completed | MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer NCT02536794 | Northwestern University | Phase 2 |
| Completed | Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Earl NCT02526498 | Rutgers, The State University of New Jersey | Phase 2 |
| Terminated | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Bre NCT02457910 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Completed | Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D) NCT02186015 | Loyola University | Phase 2 |
| Completed | Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic NCT02219789 | Mayo Clinic | Phase 1 |
| Terminated | A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With NCT02202746 | Clovis Oncology, Inc. | Phase 2 |
| Completed | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients NCT02152943 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Broccoli Sprout Extract in Treating Patients With Breast Cancer NCT01753908 | Roswell Park Cancer Institute | EARLY_Phase 1 |
| Terminated | Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery NCT01754519 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck C NCT01846091 | Mayo Clinic | Phase 1 |
| Terminated | Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III NCT01776008 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Brea NCT01750073 | University of Nebraska | Phase 2 |
| Completed | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Br NCT01697293 | Prescient Therapeutics, Ltd. | Phase 1 / Phase 2 |
| Completed | FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Nega NCT01928186 | University of Washington | N/A |
| Completed | MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal NCT01344031 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer NCT01319539 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metasta NCT01281150 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer NCT01281163 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cance NCT01149356 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Canc NCT02149173 | University of Washington | N/A |
| Completed | Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or NCT00785291 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cance NCT00390455 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Re NCT00118157 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive NCT00338728 | M.D. Anderson Cancer Center | Phase 2 |